Mark G. Kris, MD, Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses how the crizotinib clinical trial changed the paradigm for treating patients with lung cancer who harbor an EML4-ALK translocation, at the 2010 ASCO Annual Meeting.

On August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non—small cell lung cancer (NSCLC).

Videos

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York on the EML4-ALK Translocation

Dr. Kris on the EML4-ALK Translocation in Lung Cancer

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the goal in cancer care has been to know enough about cancer to find a characteristic that is a weakness to the cancer and exploit it.

When discussing the clinical trial Kris explains that only patients with an EML4-ALK translocation were allowed into the crizotinib clinical trial. He compares crizotinib to imatinib in BCR-ABL patients.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on the Crizotinib Clinical Trials 

Dr. Kris on the Crizotinib Clinical Trials 

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes that the average lung cancer patient is over the age of 70, although they are truly the majority they are treated like the minority in clinical trials. In many cases these elderly patients are not receiving the guideline recommended care.

Dr. Mark G. Kris from Memorial Sloan-Kettering on Caring for Elderly Lung Cancer Patients

Dr. Kris on Caring for Elderly Lung Cancer Patients

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses EGFR mutation testing for patients with lung cancer, at the 2010 ASCO Annual Meeting. 

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York Discusses EGFR Mutation Testing

Mark G. Kris, MD, FASCO

Articles

Dr. Kris on the EML4-ALK Translocation in Lung Cancer

Dr. Kris on the Crizotinib Clinical Trials

Dr. Kris on Caring for Elderly Lung Cancer Patients

Dr. Kris Discusses EGFR Mutation Testing